Diagnostics

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

At MD&M West 2026, Boyd showcases how materials science and regulatory expertise are the unsung heroes behind the next wave of medical wearables.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

With backing from a top hospital, VolitionRx seeks reimbursement for its Nu.Q® blood test, aiming to transform lung cancer care in France and beyond.

Known for non-opioid pain relief, Scilex is diversifying with a major investment in a stealthy diagnostic firm, hinting at a new data-driven strategy.

WXIA-TV's 'Help That Harms' investigation won a duPont-Columbia Award for exposing how families were wrongly accused of abuse, leading to landmark legal reforms.

A landmark study validates Panakeia's AI, which provides critical cancer biomarker results in minutes, promising to revolutionize patient care globally.

A massive NHS trial in The Lancet shows AI-powered stethoscopes dramatically improve early detection of heart disease. Is this the future of primary care?

With new manufacturing deals, CS Diagnostics is set to enter the competitive global hygiene market, targeting infection control from hospitals to homes.

As new CDC data reveals autism affects 1 in 31 children, one provider is rapidly expanding its workforce and centers to address a growing public health crisis.

ENA Respiratory's INNA-051 nasal spray, a virus-agnostic shield, has begun Phase II trials, offering new hope for high-risk communities.

The new SecureFlex™ device aims to improve tissue sampling for diseases like pancreatic cancer, enabling more precise diagnoses and personalized treatments.

A new study reveals an AI-powered metric better predicts sleep apnea symptoms than traditional tests, promising more accurate diagnoses, especially for women.

With a new $7.5M investment, Elysium Therapeutics is advancing SOOPR, a long-acting overdose rescue agent designed to combat the deadly fentanyl rebound.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new study in Nature Medicine shows a fasting-mimicking diet led to high remission rates in Crohn's patients, heralding a new era for 'Food as Medicine'.

New data reveals Orasis Pharma's Qlosi eye drops offer a 'pupil selective' approach to presbyopia, promising fewer side effects than rival treatments.

Myriad Genetics is launching a new cancer test that promises to detect recurrence earlier than ever. But can it win in a competitive market?

A new partnership combines radiation-free imaging with advanced AI analytics, aiming to revolutionize breast cancer detection and patient care.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.